Product Center
Ab&B Bio-Tech Co., Ltd. JS Quadrivalent Influenza Virus Subunit Vaccine Marketing Application Has Been Accepted by the National Medical Products Administration!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.
Ab&B Bio-Tech Co., Ltd. JS Quadrivalent Influenza Virus Subunit Vaccine Marketing Application Has Been Accepted by the National Medical Products Administration!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21 16:16
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.
Source: CDE Website
The Ab&B Bio-Tech Co., Ltd. JS quadrivalent influenza virus subunit vaccine is a component vaccine containing a new antigen form, characterized by high purity, low vaccination side effects, and good safety. In 2016, the company applied for clinical trials of the quadrivalent influenza virus subunit vaccine using its own patented technology. In 2017, the company obtained clinical approval for two Class 1 biological new drugs in adult and pediatric dosage forms. From 2018 to 2021, the Phase I/III clinical trial was successfully completed, and all relevant trial results reached clinical endpoints, showing significant positive results in immunogenicity and safety.
The clinical results show that the full-dose unadjuvanted (0.5ml) quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted for the company's marketing application, is a safe and effective influenza vaccine that can provide broader and sufficient protection against seasonal influenza viruses. This vaccine is expected to serve as an important member of the influenza prevention strategy and contribute to China's efforts in the global prevention and control of influenza virus outbreaks and infections.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
